Health & Medical Archives | Page 6 of 242 | Be Korea-savvy

Archive by category Health & Medical

Curia Commits to SBTi Net-Zero Standard

Curia Commits to SBTi Net-Zero Standard

ALBANY, N.Y., Oct. 08, 2024 (Korea Bizwire) –  Curia, a leading contract research, development and manufacturing organization, today announced its commitment to set near- and long-term company-wide greenhouse gas (GHG) emission reductions in line with science-based net-zero with the Science Based Targets initiative (SBTi). To achieve this goal, Curia will be investing resources over the next [...]

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such [...]

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II  study1 Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE-Cirrhosis in those with [...]

Curia Unveils Brand Refresh at CPHI WW in Milan

Curia Unveils Brand Refresh at CPHI WW in Milan

The refined brand highlights Curia’s key capabilities and personalized approach across small molecules, generic APIs and biologics ALBANY, N.Y., Oct. 07, 2024 (Korea Bizwire) – Curia, a leading contract research, development and manufacturing organization, today unveiled its refreshed brand. The update introduces refined corporate messaging and a new brand hierarchy, highlighting the breadth of Curia’s [...]

Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia’s healthcare transformation strategy

Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia’s healthcare transformation strategy

October 7, 2024 Jakarta, Indonesia and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Siloam Hospitals Group, Indonesia’s leading private healthcare provider, have signed a Memorandum of Understanding (MoU) to advance AI capabilities and development in the healthcare sector in Indonesia. The strategic collaboration, in partnership with the [...]

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda

WASHINGTON, Oct. 05, 2024 (Korea Bizwire) – The Sabin Vaccine Institute has provided its investigational Marburg vaccine to Rwanda to support the ongoing outbreak response. The initial shipment of approximately 700 vaccine doses will be used in a trial targeting frontline workers, including healthcare professionals who have been hardest hit by the deadly virus.  Sabin [...]

Dark Horse Consulting Group Acquires BioTechLogic, Inc.

Dark Horse Consulting Group Acquires BioTechLogic, Inc.

Combined organization to offer strategic advisory, operations, and technical consulting across the biopharma industry WALNUT CREEK, Calif. and CAVE CREEK, Ariz. and BOSTON, Oct. 03, 2024 (Korea Bizwire) – Dark Horse Consulting Group (“DHC”), the longstanding global leader in strategic and operational consulting in the field of cell and gene therapy (“CGT”), is delighted to announce the [...]

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva’s Pivot to Growth strategy and adds to the company’s biosimilar portfolio Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide TEL AVIV, ISRAEL and MADRID, Oct. [...]

Pioneering hospitals take major steps towards decarbonizing healthcare with Philips

Pioneering hospitals take major steps towards decarbonizing healthcare with Philips

October 3, 2024 Philips helps healthcare organizations worldwide assess and mitigate their environmental impact while enabling better care and better care outcomes for more patients at lower cost Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced significant greenhouse gas (GHG) emissions reduction results following collaboration with customers [...]

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, [...]